$PBIO VALUATION: "We are initiating coverage on Pressure BioSciences with a valuation of $4.44 per share, based on a sum-of-the-parts NPV less corporate overhead. Our NPV uses an 11% discount rate across the business. We ve modeled for $6 million of debt funding through 2024. The average prospective P/E valuations for our peer group are in the mid-twenties for 2019-2020. P/S ratios range widely from a low of 3.4x for Bruker Corporation (BRKR-$44.42) to 6.1x for Waters Corporation (WAT-$222.53).

PBIO currently trades around 2x 2019 revenue estimates. It s important to note that PBIO s publicly-traded peers are multinational companies with broad product lines, significant marketing resources and good financial and trading liquidity, all of which likely contribute to PBIO s lower relative valuation." https://s1.q4cdn.com/460208960/files/News/201..._Senko.pdf